Market Trends - The current market situation is characterized by maximum uncertainty, with potential opportunities for high-quality blue-chip companies affected by recent downturns [2] - Historical data shows that selling during periods of market distress, such as the Silicon Valley Bank collapse or COVID-19, resulted in missing significant recoveries of 78% and 198% respectively [3] - The timing of geopolitical events, such as the Iran war, is crucial; a shorter conflict may allow the economy to continue growing, while a prolonged one could lead to stagnation [2][3] Healthcare Stocks - A list of 11 high growth healthcare stocks has been compiled based on a high 5-year revenue growth rate (over 25%) and popularity among elite hedge funds as of Q3 2025 [6] - The methodology for selecting these stocks involved using stock screeners and analyzing hedge fund sentiment [6][7] Zai Lab Limited (NASDAQ:ZLAB) - Zai Lab Limited reported a 17% year-over-year revenue growth to $127.6 million for fiscal Q4 2025 and a 15% growth to $460.2 million for the full year [10] - The company is on track for its first global oncology launch with Zocilurtatug pelitecan, expected to complete three registration-enabling studies by the end of 2026 [10][11] - Zai Lab is advancing a differentiated global pipeline, including several key therapies and regional programs, with commercial launch preparations for KarXT in China underway [11][12] ImmunityBio Inc. (NASDAQ:IBRX) - ImmunityBio received a warning letter from the FDA regarding misleading promotional communications for its product Anktiva, which has led to a directive to cease certain advertisements [13][14] - The company is a clinical-stage immunotherapy firm focused on developing next-generation therapies for cancer and infectious diseases [15]

翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 再鼎醫藥有限公司 呈交日期： 2026年3月27日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 FF305 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 09688 | 說明 | 普通股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 | | 佔有關 ...

Revenue Growth - Product revenue increased by $59.6 million (or 15%) to $457.2 million, driven by strong demand for DINGYAOLE and increased sales of NIUZAILA, despite some supply constraints during the year [4] - Total revenue for 2025 reached $460,156,000, a 15.4% increase from $398,988,000 in 2024 [20] - Net product revenue after rebates and returns for 2025 was $457.182 million, compared to $397.614 million in 2024, reflecting a year-over-year increase of about 15% [79] - The company reported a significant increase in net revenue from the product "Dingyoule," which rose to $22.912 million in 2025 from $3.305 million in 2024, marking a growth of over 594% [80] - The net revenue from the product "Niuzaile" increased to $60.836 million in 2025 from $43.199 million in 2024, representing a growth of approximately 40.9% [80] Financial Performance - Net loss decreased by $81.6 million (or 32%) to $175.5 million, attributed to product revenue growth outpacing net operating expenses and a shift from foreign exchange losses to gains, although offset by reduced interest income [4] - Basic and diluted loss per share was $0.16, a decrease of 38% from $0.26 [4] - Operating loss decreased to $229,434,000 in 2025 from $282,117,000 in 2024, indicating an 18.7% improvement [20] - Net loss for 2025 was $175,537,000, an improvement from a net loss of $257,103,000 in 2024, representing a 31.7% reduction in losses [21] Expenses Management - R&D expenses decreased by $13.6 million (or 6%) to $220.9 million, mainly due to resource optimization and efficiency improvements, partially offset by increased clinical trial costs [4] - Selling, general and administrative expenses decreased by $21.1 million (or 7%) to $277.6 million, primarily due to resource optimization and efficiency improvements [4] - Research and development expenses were $220,904,000, down from $234,504,000 in 2024, a decrease of 5.8% [20] - The total remuneration for the CEO and executive directors in 2025 was $17,650,000, a decrease of 2.3% from $18,068,000 in 2024 [145] Assets and Liabilities - Total assets decreased from $1,185,753,000 in 2024 to $1,172,384,000 in 2025, a decline of approximately 1.1% [19] - Total liabilities rose from $344,855,000 in 2024 to $456,884,000 in 2025, an increase of approximately 32.5% [19] - Shareholders' equity decreased from $840,898,000 in 2024 to $715,500,000 in 2025, a decline of about 15% [19] - Cash and cash equivalents increased significantly from $449,667,000 in 2024 to $679,573,000 in 2025, representing a growth of about 51.1% [19] Cash Flow and Financing - Cash used in operating activities was $150,789,000 in 2025, an improvement from $214,869,000 in 2024 [23] - Financing activities generated a net cash inflow of $72,353,000 in 2025, compared to $349,889,000 in 2024 [23] - The company has secured a non-committed financing letter with Bank of China for up to $100 million, backed by restricted cash of the same amount [99] - The company has established a credit line with Bank of Communications for up to RMB 300 million (approximately $41.1 million), expiring in September 2025 [103] Inventory and Accounts Receivable - Inventory net increased from $39,875,000 in 2024 to $74,745,000 in 2025, reflecting an increase of approximately 87.2% [19] - Accounts receivable increased by $20.9 million to $106.1 million, primarily due to increased product revenue [197] - Accounts payable rose from $100,906,000 in 2024 to $141,608,000 in 2025, an increase of about 40.5% [19] Taxation and Deferred Tax Assets - The company incurred a current tax expense of $451,000 in mainland China for 2025, with a deferred tax benefit of $(3.378) million [89] - The company expects a deferred tax asset net value of $3.4 million as of December 31, 2025, primarily related to inventory write-downs [94] - The company has a deferred tax asset related to capitalized research and experimentation of $49,331 million for 2025, up from $38,215 million in 2024 [93] Strategic Initiatives and Market Position - The company is actively pursuing market expansion and innovative drug development to address unmet medical needs in oncology, immunology, neuroscience, and infectious diseases [25] - The company aims to become a leading global biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies to improve patient health [177] - The company continues to strengthen its business through the addition of key global leadership members, including the appointment of Dr. He as Senior Vice President and Chief Business Officer [170] Collaboration and Licensing Agreements - The company has entered into a licensing agreement with Zenas for the development of products targeting IGF-1R, with an upfront payment of $10 million and potential additional payments up to $117 million [109] - The company has a licensing agreement with Paratek for the exclusive rights to develop and commercialize products containing Omadacycline in the Greater China region, with potential milestone payments of up to $40.5 million based on sales [119] - The company has a collaboration and licensing agreement with Pfizer for Tisotumab Vedotin, with potential milestone payments of up to $258.0 million based on development and sales [125]

Group 1 - The article discusses a series of online meetings scheduled for March 2023, focusing on various sectors including pharmaceuticals, agriculture, new energy, and chemicals [24]. - The first meeting on March 23, 2023, at 19:00, will cover a deep report on Zai Ding Pharmaceutical, presented by the chief analyst and an analyst from the pharmaceutical sector [24]. - The second meeting on March 23, 2023, at 20:00, will focus on investment strategies in the planting sector, led by the chief agricultural analyst and an agricultural analyst [24]. Group 2 - A meeting on March 25, 2023, at 20:30, will explore new opportunities in the new energy sector, specifically the seventh series of discussions, presented by the vice president and chief analyst of the electric new energy sector [24]. - On March 27, 2023, at 11:00, a session titled "Europe's Risks, China's Opportunities" will address the impact of natural gas supply shocks on the vitamin industry, led by a chemical industry analyst [24]. - The final meeting on March 27, 2023, at 15:00, will provide insights into the electronic industry for April, presented by the chief analyst of the electronic sector [24].

Investment Rating - The report maintains a "Buy" rating for Zai Lab (09688) [4][16] Core Insights - The report highlights a slowdown in commercialization growth while noting a rich pipeline of innovative products that could catalyze future growth [4][9] - Zai Lab's revenue for 2025 is projected to grow by 15% year-on-year, reaching USD 460 million, with a reduction in net losses from USD 257 million in 2024 to USD 176 million in 2025 [12][19] - The company has a strong cash position of approximately USD 790 million as of the end of 2025, which supports ongoing research and development efforts [12][19] Financial Performance Summary - In 2025, total revenue reached USD 460 million, with product revenue contributing USD 457 million, marking a 15% increase year-on-year [12][13] - R&D expenses decreased by 6% year-on-year to USD 221 million, with the R&D expense ratio dropping from 59% in 2024 to 48% in 2025 [12][19] - The company expects to launch multiple new products in 2026, including KarXT and TIVDAK, which have received or are expected to receive regulatory approvals [14][15] Sales Growth and Product Performance - Significant sales growth was observed in key products, with XACDURO sales increasing by 593% to USD 23 million and NUZYRA sales rising by 41% to USD 61 million in 2025 [13][8] - The report notes that ZEJULA's sales remained stable at USD 189 million due to changes in the competitive landscape of the PARP market [13][8] Pipeline Catalysts - The report identifies several upcoming catalysts in 2026, including data readouts for various clinical trials and the initiation of global studies for new treatments [15][9] - Key products in the pipeline include Zoci, Efgartigimod, and Povetacicept, which are expected to provide significant data updates in the near future [15][9]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不會對因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Zai Lab Limited 再鼎醫藥有限公司* ( 於開曼群島註冊成立的有限公司 ) (股份代號: 9688) 董事會行動通告 再鼎醫藥有限公司（「本公司」）謹此宣佈，本公司董事會（「董事會」）將於 2026年 3月 26日 （星期四，美國東部時間）/2026 年 3 月 27 日（星期五，香港時間）審議及批准（其中包括）根 據香港聯合交易所有限公司證券上市規則（「香港上市規則」）編製的本公司及其附屬公司截至 2025 年 12 月 31 日止年度的年度業績（「年度業績」）及其發佈。本公司先前已公佈其根據美國 公認會計準則（「美國公認會計準則」）編製的年度業績，並於 2026 年 2 月 26 日（星期四，美 國東部時間/香港時間）以表格 10-K 向美國證券交易委員會（「美國證交會」）提交其截至 2025 年 12 月 31 日止年度的年度報告。 本公司將根據香港上市規則刊發的年度業績與本公司先 ...

Investment Rating - The report gives a "Buy" rating for Zai Lab (09688) [10] Core Insights - Zai Lab is focusing on accelerating the clinical development of its core pipeline, with three key clinical studies for Zoci expected to catalyze growth in 2026 [3][4][10] - The company has successfully commercialized eight products in China, contributing to steady revenue growth and a significant reduction in losses [21][23] - Zai Lab's innovative pipeline includes promising candidates like KarXT, which is expected to change the treatment paradigm for schizophrenia, and Zoci, targeting small cell lung cancer [8][9][10][32] Summary by Sections 1. Company Overview - Zai Lab, founded in 2014, is an innovative biopharmaceutical company focused on addressing unmet medical needs in oncology, immunology, and neuroscience through the discovery, development, and commercialization of innovative products [17] 2. Clinical Pipeline - Zoci is undergoing three pivotal clinical studies in 2026, targeting second-line and first-line small cell lung cancer (SCLC) and neuroendocrine cancers (NECs) [4][37] - ZL-1503 has completed its first patient dosing and is expected to support phase 2 clinical development for atopic dermatitis [5][29] - The company is also advancing ZL-6201 and ZL-1222 in global clinical studies, with significant data expected in 2026 [5][29] 3. Market Potential - The approval of Zai Lab's products, including KarXT for schizophrenia, is anticipated to create new growth opportunities, with plans for commercialization in 2026 [23] - The company has seen a compound annual growth rate of 221.3% in revenue from 2018 to 2025, with core products like Niraparib leading sales [21][23] 4. Financial Projections - Revenue forecasts for 2026, 2027, and 2028 are projected at $483 million, $561 million, and $780 million respectively, with net losses expected to narrow significantly over the same period [10][13]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示，概不會對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任何損失承擔任何責任。 Zai Lab Limited 再鼎醫藥有限公司* （於開曼群島註冊成立的有限公司） （股份代號：9688） 授出購股權、受限制股份單位及業績股份單位 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。董事會宣佈，本公司於授 出日期根據2024年股權激勵計劃授出部分購股權、受限制股份單位以及業績股份單位。 授出購股權 | 承授人數目： 1 | | | --- | --- | | 承授人類型： | 杜瑩博士，本公司董事、董事長兼首席執行官 | | 所授出購股權數目 | 353,430 | | （以美國存託股份計）： | | | 所授出購股權涉及的相關股份 | 3,534,300 | | 數目： | | | 所授出購股權的行使價： | 每股美國存託股份19.34美元（每股股份約15.08港元） | | 股份於授出日期的收市價： | 每股美國存託股份19.07美元（每股股份約14.87 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示，概不會對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任何損失承擔任何責任。 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。董事會宣佈，本公司於授 出日期根據2024年股權激勵計劃授出部分購股權、受限制股份單位以及業績股份單位。 授出購股權 Zai Lab Limited 再鼎醫藥有限公司* （於開曼群島註冊成立的有限公司） （股份代號：9688） 授出購股權、受限制股份單位及業績股份單位 | | | 承授人類型： 僱員參與者 所授出購股權數目 374,220 （以美國存託股份計）： 所授出購股權涉及的相關股份 數目： 3,742,200 所授出購股權的行使價： 每股美國存託股份19.27美元（每股股份約15.03港元） 股份於授出日期的收市價： 每股美國存託股份19.27美元（每股股份約15.03港 元），即於2026年3月4日（美國東部時間）納斯達克 報收之收市價 每股股份14.24港元，即於2026年3月4日（香港時間） 聯交所報收之收市價 1 ...

Investment Rating - The report maintains an "Overweight" rating for the industry [2] Core Insights - The Alzheimer's Disease (AD) sector is transitioning from "symptom improvement" to "disease-modifying therapies (DMT)" in 2026, marking a critical growth phase with the approval of two major amyloid-beta (Aβ) antibody drugs and the emergence of new diagnostic technologies [4][11] - 2026 is expected to be a pivotal year for AD, with significant conferences serving as platforms for academic exchange and market negotiations, focusing on drug administration convenience, the rise of Chinese voices, and the reassessment of diagnostic value [15] - Key drug progress in 2026 includes regulatory decisions on AXS-05 and Leqembi, which could expand the AD treatment market significantly [17] - The AD detection field is set for large-scale clinical adoption, driven by blood tests, AI advancements, and new biomarkers, with a focus on early and precise diagnosis [19] Summary by Sections Industry Overview - The industry comprises 504 listed companies with a total market value of approximately 69,490.56 billion [2] Market Trends - The investment logic is shifting from solely "new drug development" to a comprehensive ecosystem of "early screening + precise treatment + full-course management" [4][11] Key Drug Developments - Major drug approvals and data releases are anticipated throughout 2026, including AXS-05 and Leqembi, which are crucial for market expansion [17][18] Diagnostic Innovations - The trend towards "blood-based" and "intelligent" diagnostics is accelerating, with significant advancements expected in blood biomarkers and AI integration in imaging [19][20] Investment Opportunities - The report highlights the increasing role of Chinese pharmaceutical companies in the global AD landscape, with notable collaborations and innovative drug developments [21][22] Clinical Trials and Research - The domestic clinical pipeline for AD is entering a phase of rapid development, with a focus on precision diagnostics and disease-modifying treatments [24]